Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
11,360 total articles
Robert Kenneth Mustard, a director at SR Bancorp, Inc. (NASDAQ: SRBK), bought 250 shares on February 2, 2026, at $17.05 per share, representing a $4,262 purchase. The filing shows Mustard now directly holds 1,250 shares. The transaction was executed under a power of attorney by William P. Taylor on February 3, 2026. Separately, SR Bancorp declared …
Scott G. Orzehoski, QNB CORP's Executive Vice President and Chief Lending Officer, sold 300 shares on January 30, 2026, and on the same day exercised stock options. The transactions occurred while QNB shares traded near a 52-week high; the bank also announced a quarterly cash dividend payable December 26, 2025.
Nucor Corporation Executive Vice President Needham Daniel R. disclosed the sale of 3,881 shares on January 30, 2026, in a Form 4 filing with the Securities and Exchange Commission. The shares were sold at $178.0 each, totaling $690818. After the trade, Needham directly holds 88298.37 shares. Separately, Nucor reported fourth-quarter 2025 results th…
Univest Financial director Natalye Paquin bought 580 shares on February 2, 2026, at $34.579 per share, totaling $20,055. Paquin also received 1,766 shares on January 31, 2026, following the vesting of restricted stock units, and holds 1,283 RSUs scheduled to vest on January 31, 2028. Separately, Univest reported stronger-than-expected fourth-quarte…
Robert Clark Nickles Jr., a director at First Financial Bankshares (FFIN), purchased 629 shares on February 2, 2026, for $20,467 through an indirect limited liability company. The bank also promoted James Alexander to Executive Vice President and Head of Commercial Banking as part of its succession planning. InvestingPro metrics cited in the filing…
Venu Holding Corp's CEO and chairman, Jay W. Roth, purchased 5,000 shares of the company's common stock on January 30, 2026, for $27,750. The company has released preliminary fourth-quarter revenue guidance, reported a large increase in total assets through 2025 and withdrew a proposed $75 million public stock offering due to unfavorable market con…
First Community Corp director Reynolds E. Leland bought 500 shares of the company's common stock on February 2, 2026, investing $14,834. After the purchase he owns 30,930 shares including deferred stock units. The bank posted $19.2 million in net income for 2025 and completed its acquisition of Signature Bank of Georgia on January 8, 2026.
Crane Co director Sanjay Kapoor reported a purchase of 2,814 shares on January 29, 2026, at $177.68 per share for a total of $499,991, according to a Form 4 filing. Separately, Crane Co's Q4 2025 results showed earnings per share of $1.53, in line with forecasts, while revenue came in at $581 million versus an expected $624.82 million, a shortfall …
Director Jennifer Pollino purchased 1,500 shares of Crane Co on January 29, 2026, spending $276,435 at $184.29 per share. The transaction comes as Crane Co reported fourth-quarter 2025 results with earnings per share matching forecasts at $1.53, while revenue of $581 million fell short of the $624.82 million analysts had expected. The earnings rele…
Kevin Hochman, president and CEO of Brinker International, sold 66,000 shares on January 29, 2026, for a total of $10,580,460 under a Rule 10b5-1 plan. He also gifted 2,000 shares the following day. Together, these moves leave him with 129,824 direct shares. Separately, Brinker reported fiscal 2026 second-quarter adjusted diluted EPS of $2.87 and r…
Marshall Urist, Executive Vice President, Research & Investments at Royalty Pharma PLC (NASDAQ:RPRX), sold 20,000 Class A Ordinary Shares on January 30, 2026, for about $821,810 under a pre-arranged 10b5-1 trading plan. Royalty Pharma reported a record $10 billion in the 2025 royalty funding market, completed its acquisition of PTC Therapeutics’ re…
Lindblad Expeditions insider Sven-Olof sold 183,639 shares across two days for roughly $3.07 million under a Rule 10b5-1 plan. The disposals leave him with 11,172,779 shares. The transactions come after the company reported third-quarter 2025 revenue ahead of expectations but an earnings-per-share shortfall, and announced a mandatory conversion of …
Adrian W. Quartel, Chief Medical Officer of Zevra Therapeutics (ZVRA), sold 4,533 shares on January 30, 2026, for about $40,035 at a weighted average price of $8.8321. The transactions recorded on a Form 4 also show the grant of restricted stock units and options and the exercise of options to acquire additional shares. Zevra's stock trades above t…
KeyCorp Chief Human Resources Officer Angela G. Mago sold 62,850 shares of KeyCorp common stock on January 29, 2026, for a total of $1.35 million, at prices between $21.54 and $21.55. On the same day she exercised options to acquire 62,850 shares at $10.49, for a total of $659296. After the transactions, Mago directly holds 261,415 shares, a figure…
John Taylor Maloney Fitzgerald, President and CEO of Kingsway Financial Services Inc., purchased 183 shares at $13.69 on February 2, 2026, for $2,505 through the company ESPP. The transaction raises his direct holdings to 1,460,086 shares. The purchase coincides with a 70% one-year share gain and recent third-quarter 2025 revenue growth, but Invest…
Palomar Holdings NASDAQ:PLMR Chief People Officer Timothy Carter sold 254 restricted stock units on January 29, 2026 for $122.0415 per share, generating $30,998. The transaction coincided with the vesting of 610 RSUs and was carried out to satisfy minimum statutory tax withholding. Separately, Palomar reported a robust third quarter for 2025, beat …
Brian Birchler, Executive Vice President, Corporate and Development Operations at Ionis Pharmaceuticals, sold 6,179 shares on January 30, 2026, for about $513,047, while having acquired 11,991 shares the day prior through vesting of performance-based restricted stock units. The transaction occurred as IONS traded close to its 52-week high of $86.15…
Mark N. Tompkins, a reported 10% owner of Aeluma, Inc. (ALMU), sold a total of $1.53 million in common stock across several trades executed between January 29 and February 2, 2026. The transactions covered a range of prices from $15.74 to $17.16. After the disposals, Tompkins retains direct ownership of 1,824,988 Aeluma shares. ALMU is trading at $…
Patrick R. O’Neil, Executive Vice President, CLO and General Counsel of Ionis Pharmaceuticals, sold 6,179 shares on January 30, 2026, for about $516,153 and recorded the vesting of 11,991 performance-based restricted stock units the prior day. The transactions leave O’Neil with 71,983 shares. Separately, Ionis disclosed recent regulatory and clinic…
Eric Swayze, executive vice president of research at Ionis Pharmaceuticals, sold 6,179 shares on January 30, 2026, for about $512,446. The transaction occurred as Ionis shares trade near a 52-week high and follow a separate vesting-related acquisition of 11,991 shares on January 29. The moves come alongside regulatory approvals, positive clinical d…
Ionis Pharmaceuticals CEO Brett P. Monia sold roughly $5.2 million worth of company shares on January 30, 2026, after receiving a larger grant the prior day from vested performance-based restricted stock units. The stock is trading near its 52-week high, supported by recent regulatory approvals and positive Phase 3 trial results, while company fina…
Eugene Schneider, executive vice president and chief clinical development officer at Ionis Pharmaceuticals (IONS), sold 6,179 shares on January 30, 2026, for $515,629, after receiving 11,991 performance-based restricted stock units that vested a day earlier. The sale occurred at prices close to the stock’s 52-week high, while the company has seen s…
PubMatic CEO Rajeev K. Goel sold a combined 65,592 shares of Class A Common Stock in late January and early February 2026 for roughly $477,250. The trades included transactions executed through The Goel Family Trust under a Rule 10b5-1 plan. Separately, Goel exercised options and converted Class B shares into Class A shares. PubMatic also reported …
Charles R. Schwab, Co-Chairman of Charles Schwab Corporation (NYSE: SCHW), sold 145,650 shares on January 29, 2026, for roughly $15 million at a weighted average price of $103.1649. The transaction leaves him with substantial direct and indirect holdings. The firm also announced a 19% dividend increase and an internal leadership change at Charles S…
Solid Biosciences Inc. Chief Financial Officer Kevin Tan sold 26,837 shares of common stock on February 2, 2026, in a set of transactions that generated about $172,747. The disposition, reported on a Form 4, was executed to meet withholding tax obligations tied to the recent vesting of performance stock units. The company continues to report clinic…
